Systemic administration of 3-bromopyruvate in treating disseminated aggressive lymphoma

• Published in: Translational research : the journal of laboratory and clinical medicine Vol. 159; no. 1; pp. 51 - 57
• Main Authors: Schaefer, Niklaus G, Geschwind, Jean F, Engles, James, Buchanan, Julia W, Wahl, Richard L
• Format: Journal Article
• Language: English
• Published: United States Mosby, Inc 2012
• Subjects: Animals; Antineoplastic Agents - administration & dosage; Cell Proliferation - drug effects; Disease Models, Animal; Enzyme Inhibitors - administration & dosage; Glycolysis - drug effects; Humans; Internal Medicine; Lethal Dose 50; Lymphoma, Non-Hodgkin - drug therapy; Lymphoma, Non-Hodgkin - metabolism; Male; Mice; Mice, SCID; Pyruvates - administration & dosage; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; severely combined immunodeficient; 2-deoxyglucose; FDG; 2-DG; 3BrOP; fludeoxyglucose; green fluorescent protein; SCID; GFP; adenosine triphosphate; 3-bromopyruvate; 3-BrPA; ATP; 3-bromo-2-oxopropionate-1-propyl ester

The Warburg hypothesis states that aggressive cancers obtain much of their adenosine triphosphate (ATP) by metabolizing glucose directly to lactic acid. As a result of its high tumor selectivity, 3-bromopyruvic acid (3-BrPA), a well-known inhibitor of energy metabolism, has been proposed as a specif...